

TRANSLOCATION-transfer (TT)

Mathias Winterhalter, Jacobs University Bremen m.winterhalter@jacobs-university.de

Philip Gribbon, Fraunhofer IME, Hamburg; Philip.Gribbon@ime.fraunhofer.de

In response to the pharmaceutical industry stepping back from antibiotic discovery, multiple public efforts, including the JPIAMR and IMI ND4BB, as well as the efforts of Biomedical Science (BMS) European Research Infrastructures community have stepped in to fill the gap. In **Translocation-transfer (TT)**, (<https://www.eu-openscreen.eu/projects/translocation-transfer/overview.html>) we will set up a knowledge sharing network, bringing together experts from with two major publically funded programs, with the goal to improve the process of academically driven antibiotic drug discovery by capitalising on recently gained insights into a key bottleneck in anti-bacterial research, namely how compound penetration properties determine efficacy and resistance properties. Three existing communities who will form the **TT** network are: i) the partners associated with the multinational program *Translocation* (www.translocation.eu), part of IMI ND4BB; ii) partner sites from EU-OPENSSCREEN, the European Research Infrastructure for chemical biology and screening (www.eu-openscreen.eu) and iii) partners from the wider global community working on AMR issues and research. *Translocation* (1/2013-6/2018) was one of the largest antibiotic research programs in the world specifically devoted to understanding and to devising ways of increasing antibiotic penetration into bacteria. EU-OPENSSCREEN began operation in April 2018 and runs chemical biology and academic drug discovery projects per year across a network of 25 screening sites, based in 8 European countries on behalf of users from across Europe. It is anticipated that at least 20% of EU-OPENSSCREEN projects will involve antibiotic drug discovery element. The initial goal of the TT network will be to transfer knowledge between *Translocation* and EU-OPENSSCREEN to fully incorporate compound permeation and efflux considerations into academic antibiotic drug discovery. We have the active participation of the Pew Charitable Trust, which will contribute to the long term systematic dissemination of findings from the co-funded funded *Translocation* project to help academic antibiotic drug discovery efforts on a global scale.